Korsana Biosciences announced a $175 million Series A to advance KRSA‑028, an anti‑amyloid antibody aimed at Alzheimer’s disease, and launched out of Paragon Therapeutics with plans for clinical testing in 2027. Investors including Fairmount, Venrock and Wellington Management backed the company at formation. Korsana’s strategy mirrors existing anti‑amyloid approaches but emphasizes blood‑brain barrier delivery and antibody engineering. The funding will underwrite IND‑enabling work and early clinical development as the company prepares to enter a crowded Alzheimer’s antibody landscape that already includes approved agents and multiple late‑stage competitors.